Open-label Extension Study of Brazikumab in Crohn's Disease
An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE) An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely A ...